NASDAQ:ELDN

Eledon Pharmaceuticals Q4 2025 Earnings Results & Report

Eledon Pharmaceuticals logo
$1.78 -0.12 (-6.32%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.79 +0.01 (+0.73%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eledon Pharmaceuticals beat analyst earnings expectations in its Q4 2025 results, released March 19, 2026. The company reported EPS of -$0.10 versus the -$0.20 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Q4 2025 Earnings FAQ

Eledon Pharmaceuticals (NASDAQ:ELDN) reported earnings of -$0.10 per share for Q4 2025, beating the consensus estimate of -$0.20. The report was announced on Thursday, March 19, 2026.

Eledon Pharmaceuticals Earnings Headlines

What is Noble Financial's Estimate for ELDN FY2026 Earnings?
Eledon Pharmaceuticals (NASDAQ:ELDN) Raised to Sell at Wall Street Zen
432 miles southeast of Washington, DC…
Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip maker for nearly four decades, including AMD, Intel, NVIDIA, Samsung and Taiwan Semiconductor. Washington is set to declare it a national strategic resource and ban its export. Apple, NVIDIA and Amazon have committed over $2 trillion, and Morgan Stanley estimates a $10 trillion economic boom. One small U.S. mining company sits at the center of it.tc pixel
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS).

Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS. The therapy is experimental and has not been approved for commercial use.

Eledon is headquartered in Irvine, California. The company’s work is focused on research and clinical development; it does not currently offer an approved commercial product.

View Eledon Pharmaceuticals Profile